Dr. Andrew Nunn MRC Clinical Trials Unit, UK1 Talk
Andrew Nunn has been working in clinical trials and epidemiological research since 1966 when he joined the Medical Research Council's Tuberculosis & Chest Diseases Unit as a statistician. He is currently Head of Division Without Portfolio within the newly formed MRC Clinical Trials Unit with responsibility for developing trials in... read moreneglected areas. Currently, as an Associate Director of the Trials Unit, he is an investigator and senior statistician on three international Phase III trials of tuberculosis treatment. Two of the trials, REMox and RIFAQUIN, are assessing the potential role of moxifloxacin in shortening tuberculosis chemotherapy in drug sensitive disease from six to four months. Andrew is co-chief investigator on STREAM, a Phase III trial assessing the efficacy of the 9 month Bangladesh regimen in comparison with WHO approved standardised regimens for MDR-TB.